MiNK Therapeutics (INKT) Change in Accured Expenses (2020 - 2026)

MiNK Therapeutics has reported Change in Accured Expenses for 7 years, with the latest figure at $206262.0 in Q1 2026.

• Quarterly Change in Accured Expenses rose 103.87% year-over-year to $206262.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $825287.0 (up 233.75% YoY) and the FY2025 annual result came in at $720196.0, up 282.9% from the prior year.
• Change in Accured Expenses fell to $206262.0 in Q1 2026 per INKT's latest filing, from $583257.0 in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $1.9 million in Q4 2022 and troughed at -$784295.0 in Q4 2024.
• A 5-year average of $351925.4 and a median of $206262.0 in 2026 frame the typical range for Change in Accured Expenses.
• The sharpest annual moves came in 2022 and 2023: Change in Accured Expenses soared 713.57% in 2022, then tumbled 10483.61% in 2023.
• Over 5 years, Change in Accured Expenses stood at $1.9 million in 2022, then plunged by 32.09% to $1.3 million in 2023, then plunged by 162.02% to -$784295.0 in 2024, then soared by 174.37% to $583257.0 in 2025, then slumped by 64.64% to $206262.0 in 2026.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered $206262.0, $583257.0, and $52659.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.